The combination of SDT with an immunoadjuvant, such as the agonist of toll-like receptors 7 and 8 (TLR7/8), resiquimod (R848), is hypothesized to induce stronger anti-tumor immunity. This evidence concerns the gene TLR7 and neoplasm.